CA3053491A1 - Procedes pour prevenir par prophylaxie, ralentir l'evolution ou traiter la maladie d'alzheimer - Google Patents

Procedes pour prevenir par prophylaxie, ralentir l'evolution ou traiter la maladie d'alzheimer Download PDF

Info

Publication number
CA3053491A1
CA3053491A1 CA3053491A CA3053491A CA3053491A1 CA 3053491 A1 CA3053491 A1 CA 3053491A1 CA 3053491 A CA3053491 A CA 3053491A CA 3053491 A CA3053491 A CA 3053491A CA 3053491 A1 CA3053491 A1 CA 3053491A1
Authority
CA
Canada
Prior art keywords
patient
blood
high density
density lipoproteins
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3053491A
Other languages
English (en)
Inventor
Hollis Bryan BREWER, Jr.
Michael M. MATIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HDL Therapeutics Inc
Original Assignee
HDL Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/876,808 external-priority patent/US20190021674A1/en
Application filed by HDL Therapeutics Inc filed Critical HDL Therapeutics Inc
Priority claimed from PCT/US2018/020502 external-priority patent/WO2018160868A1/fr
Publication of CA3053491A1 publication Critical patent/CA3053491A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Developmental Disabilities (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

La présente invention concerne des systèmes, un appareil et des procédés pour prévenir par prophylaxie ou traiter l'évolution de la maladie d'Alzheimer. L'évolution, la stabilisation ou l'amélioration des symptômes liés à la maladie d'Alzheimer (MA) sont traitées par surveillance d'un changement pathophysiologique indicatif de la MA chez un patient, sur la base de la surveillance, en déterminant si une plaque amyloïde est présente dans un espace périvasculaire du patient, en déterminant éventuellement une étendue de la plaque amyloïde dans l'espace périvasculaire, et sur la base de la présence de plaque amyloïde dans l'espace périvasculaire du patient, en déterminant un protocole de traitement pour le patient. Le protocole de traitement comprend l'administration au patient d'une composition de lipoprotéine haute densité dérivée du mélange d'une fraction sanguine avec un agent d'élimination des lipides.
CA3053491A 2017-03-01 2018-03-01 Procedes pour prevenir par prophylaxie, ralentir l'evolution ou traiter la maladie d'alzheimer Pending CA3053491A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762465262P 2017-03-01 2017-03-01
US62/465,262 2017-03-01
US201762516100P 2017-06-06 2017-06-06
US62/516,100 2017-06-06
US201762537581P 2017-07-27 2017-07-27
US62/537,581 2017-07-27
US15/876,808 2018-01-22
US15/876,808 US20190021674A1 (en) 2017-01-23 2018-01-22 Methods for Treating Cholesterol-Related Diseases
PCT/US2018/020502 WO2018160868A1 (fr) 2017-03-01 2018-03-01 Procédés pour prévenir par prophylaxie, ralentir l'évolution ou traiter la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
CA3053491A1 true CA3053491A1 (fr) 2018-09-07

Family

ID=67682480

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3053491A Pending CA3053491A1 (fr) 2017-03-01 2018-03-01 Procedes pour prevenir par prophylaxie, ralentir l'evolution ou traiter la maladie d'alzheimer

Country Status (5)

Country Link
EP (1) EP3589272A4 (fr)
JP (2) JP2020509036A (fr)
CN (1) CN110545797A (fr)
AU (1) AU2018226803A1 (fr)
CA (1) CA3053491A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217897A1 (fr) * 2018-05-11 2019-11-14 Hdl Therapeutics, Inc. Procédés de prévention prophylactique, de ralentissement de l'évolution ou de traitement de l'angiopathie amyloïde cérébrale, de la maladie d'alzheimer et/ou d'un accident vasculaire cérébral aigu
CN116662835A (zh) 2022-02-18 2023-08-29 医疗研究开发有限公司 分层方法以及分层装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496831A1 (fr) * 2002-08-26 2004-03-04 Lipid Sciences, Inc. Traitement de la maladie d'alzheimer au moyen de particules de proteine degraissees
WO2005011620A2 (fr) * 2003-07-03 2005-02-10 Lipid Sciences Inc. Procedes et appareil de creation de derives particulaires de hdl a taux de lipides reduit
PL3851447T3 (pl) * 2006-10-12 2024-03-04 Bellus Health Inc. Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy
EP2118141B1 (fr) * 2007-02-23 2014-07-30 The United States of America, as represented by the Secretary, Department of Health and Human Services Anticorps monoclonaux neutralisant les toxines de l'anthrax
US9040045B2 (en) * 2007-05-14 2015-05-26 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain

Also Published As

Publication number Publication date
JP2023071648A (ja) 2023-05-23
EP3589272A4 (fr) 2020-11-25
JP2020509036A (ja) 2020-03-26
EP3589272A1 (fr) 2020-01-08
AU2018226803A1 (en) 2019-08-29
CN110545797A (zh) 2019-12-06

Similar Documents

Publication Publication Date Title
US20180355021A1 (en) Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content
US20230355180A1 (en) Methods for Treating Cholesterol-Related Diseases
US20080214438A1 (en) Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content
US20190381070A1 (en) Methods for Prophylactically Preventing, Slowing the Progression of, or Treating Cerebral Amyloid Angiopathy, Alzheimer's Disease and/or Acute Stroke
JP2023071648A (ja) アルツハイマー病を予防的に防止し、その進行を遅らせ、または処置するための方法
WO2018160868A1 (fr) Procédés pour prévenir par prophylaxie, ralentir l'évolution ou traiter la maladie d'alzheimer
US20190070257A1 (en) Methods for Prophylactically Preventing, Slowing the Progression of, or Treating Alzheimer's Disease
US20220202857A1 (en) Systems and methods for reducing low attenuation plaque and/or plaque burden in patients
CA3099999A1 (fr) Procedes de prevention prophylactique, de ralentissement de l'evolution ou de traitement de l'angiopathie amyloide cerebrale, de la maladie d'alzheimer et/ou d'un accident vascula ire cerebral aigu
US20230140014A1 (en) Methods and Systems for Prophylactically Preventing, Slowing the Progression of, or Treating Cerebral Amyloid Angiopathy, Alzheimer’s Disease, and/or Acute Stroke
US20200171086A1 (en) Methods for Treating Lipid-Related Diseases Including Xanthomas, Carotid Artery Stenoses, and Cerebral Atherosclerosis
WO2023064794A1 (fr) Procédés et systèmes de prévention prophylactique, de ralentissement de l'évolution ou de traitement de l'angiopathie amyloïde cérébrale, de la maladie d'alzheimer et/ou d'un accident vasculaire cérébral aigu
CN113365643A (zh) 用于治疗包括黄色瘤、颈动脉狭窄和脑动脉粥样硬化的脂质相关疾病的方法
WO2022150631A1 (fr) Systèmes et méthodes permettant de réduire la plaque à faible atténuation et/ou la charge de plaque chez des patients